TAK-671 / Takeda, Samsung - LARVOL DELTA

Genetic Heterogeneity in Cowpea Genotypes (Vigna unguiculata L. Walp) Using DArTseq (GBS)-Derived Single Nucleotide Polymorphisms. (PubMed, Genes (Basel)) - "The heatmap revealed that the TVU 9596 (SB26), Orelu (SB72), 90K-284-2 (SB55), RV 403 (SB17), and RV 498 (SB16) genotypes were heterogenous. The mean values for polymorphic information content, observed heterozygosity, expected heterozygosity, major allele frequency, and the inbreeding coefficient were 0.345, 0.386, 0.345, 0.729, and 0.113, respectively. Moreover, they validated the diversity of the evaluated cowpea genotypes, which could be used for potential breeding programmes and management of cowpea germplasm."

Heterogeneity • Journal

Evidence that an unnamed isometric virus associated with potato rugose disease in Peru is a new species of torradovirus. (PubMed, Phytopathology) - "This new potato torradovirus showed high nucleotide sequence identity to an unidentified isometric virus(SB26/29), which was associated with a disease named potato rugose stunting in southern Peru characterized over two decades ago...Pairwise comparison among PotRSV isolates revealed amino acid identity values >86% in the protease-polymerase (Pro-Pol) region and >82% for the combined CPs. The closest torradovirus species, squash chlorotic leaf spot virus, shares amino acid identities of ~58% and ~41% in the Pro-Pol and the combined CPs, respectively."

Journal

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults (clinicaltrials.gov) - P1b; N=0; Withdrawn; Sponsor: Takeda; N=40 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

Age stage, two-sex life table of Habrobracon hebetor (Braconidae) on Spodoptera exigua (Noctuidae) reared on different sugar beet genotypes. (PubMed, Bull Entomol Res) - "To do so, H. hebetor was reared on S. exigua fed on 10 sugar beet genotypes, including SB26; SB27; SB29; SB33; SB34; (7112*SB36)*Sh-1-HSF-5; FC220; FC301; SBSI006; and HM 1339RZ in a growth chamber at 25 ± 1 °C, 60 ± 5% RH, and 16:8 (L: D) h photoperiod...Resistant and susceptible genotypes to S. exigua, FC301 and (7112*SB36)*Sh-1-HSF-5, respectively, were only genotypes on which H. hebetor had greater and approximately equal r compared with S. exigua. This finding indicates high capability of H. hebetor to be successfully employed against S. exigua on sugar beet genotypes which are extremely different in resistance to this pest."

Journal

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults (clinicaltrials.gov) - P1b; N=40; Not yet recruiting; Sponsor: Takeda

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • PCR

Pest categorisation of non-EU viruses and viroids of potato. (PubMed, EFSA J) - "The following viruses meet the criteria to qualify as potential Union quarantine pest: APLV, APMMV, APMoV, ChiLCV, CYSDV, PAMV, PBRSV, PVH, PVP, PVT, PYDV, PYMV, PYV, PYVV, RCVMV, SALCV, SB26/29, ToCV, ToLCNDV, ToMHaV, ToMoTV, ToSRV and ToYVSV...PotLV and WPMV do not qualify as potential Union quarantine pest, since they are not reported to have any impact. For most of the categorised viruses, the conclusions of the Panel have inherent uncertainties, due to the lack of quantitative data on their impact and/or absence or limited availability of information on the biology, epidemiology and geographical distribution."

Journal

A Phase I Study of SB26 in Healthy Volunteers (clinicaltrials.gov) - P1; N=58; Completed; Sponsor: Samsung Bioepis Co., Ltd.; Recruiting ➔ Completed

Clinical • Trial completion • F2

LOW SERUM BICARBONATE AT HOSPITAL ADMISSION IS ASSOCIATED WITH COMPLICATIONS OF PORTAL HYPERTENSION IN PATIENTS WITH CIRRHOSIS (AASLD 2019) - "Low SB in cirrhotic patients on admission is associated with AKI, HRS, PSE and GI bleeding during the hospitalization."

Clinical

A Phase I Study of SB26 in Healthy Volunteers (clinicaltrials.gov) - P1; N=58; Recruiting; Sponsor: Samsung Bioepis Co., Ltd.; Active, not recruiting ➔ Recruiting; Trial completion date: Aug 2020 ➔ Mar 2020; Trial primary completion date: Jul 2020 ➔ Mar 2020

Clinical • Enrollment open • Trial completion date • Trial primary completion date

"Patient protections for #steptherapy become law in #Wisconsin! Thank you @GovEvers for signing #SB26 to protect Wisconsinites with chronic conditions like #psoriasis and #psoriaticarthritis. #NPFadvocacy" (@NPF)

Clinical

"Thank you ⁦@SenatorTestin⁩ , Chair of the WI Senate Health and Human Services Committee, for supporting patient access by cosponsoring #SB26 to create patient protections for #steptherapy. #NPFadvocacy" (@NPF)

Clinical

"It's time to fix #steptherapy in Wisconsin! Let's get #SB26 #AB24 done in 2019! #RareAction @RareDiseases @WIStepTherapy https://t.co/jByeYzjPcS" (@RareAction)